Evaluation of T-cell response to CD3 plus CD28 monoclonal antibodies in HIV-1 infected subjects treated with highly active antiretroviral therapy.
To investigate whether highly active antiretroviral therapy (HAART) could improve CD28 molecule expression and CD28-costimulation pathway function we tested the effect of CD28-costimulation on T cell receptor/CD3 induced proliferative responses in a group of HIV-1-infected subjects with CD4+ cells>200/mmc before and after HAART. CD3-mediated responses are recovered or improved after HAART. However the ability of potentiating the responses through CD28-costimulation seemed conserved before therapy and decreased in parallel with increase of response to CD3 alone. These results confirm the integrity of CD28-pathway of costimulation in patients with CD4+ cells>200/mmc and suggest an inverse correlation between magnitude of response to CD3 alone and increase of CD3 response due to anti-CD28 addition.
Carlesimo
M
M
Department of Clinical Medicine, University of Roma La Sapienza, Italy.
Bernardi
M L
ML
Mattiacci
G
G
Pierdominici
M
M
Ferrara
R
R
Donnanno
S
S
Alario
C
C
Aiuti
F
F
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D018106:CD28 Antigens / Q000502:physiology*; D017252:CD3 Complex / Q000276:immunology*; D015497:HIV-1; D006801:Humans; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology*
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D018106:CD28 Antigens; D017252:CD3 Complex